EXOMED

Exomed is an Australian biotechnology company focused on redefining the treatment of aging by targeting it as a biological endpoint rather than an inevitable decline. The company has developed a patented platform for the production of oral, all-natural exosome-based therapeutics derived from food-grade bovine plasma. These regenerative xenogeneic extracellular vesicles (EVs) are designed to restore muscle, immune, and cognitive functions, leveraging insights from parabiosis research. Exomed's approach aims to provide a scalable and non-invasive solution to extend human healthspan and reduce the global healthcare burden associated with age-related diseases. The company is currently advancing clinical validation and is a qualifying team in the global XPRIZE Healthspan competition.